"Designing Growth Strategies is in our DNA"
Candidiasis is a fungal infection caused by yeasts from the genus Candida. Candidiasis is majorly caused due to the Candida albicans. According to, Centers for Disease Control and Prevention estimated that approximately 46,000 cases of candidiasis occur each year in the U.S. Serval symptoms can be caused by the Candida infection, where vaginal and oral infections are among the most commonly occurring symptoms, while infections to the heart are among the rarest.
Currently various antibiotics such as clotrimazole, butoconazole, miconazole, and terconazole are approved by the U.S. Food and Drug Administration for the treatment of Candidiasis. Alternatively, an oral antifungal drug, fluconazole (Diflucan) can also be used for the treatment of the Candidiasis.
Research institutes and pharmaceutical companies are focussing on studying and developing new options for the treatment or prevention of candidiasis. For instance; SCY-078, which is being studied by Scynexis, Inc., is currently in phase-3 clinical trial for the study of assessment of the safety and efficacy of SCY-078 in patients with candidiasis caused by Candida Auris (CARES).
To know how our report can help streamline your business, Speak to Analyst
At present more than 30% of the pipeline candidates for candidiasis are in phase 3. Majority of the studies have been sponsored by pharmaceutical companies, along with few studies being sponsored by research institutes.
The report on ‘Candidiasis – Pipeline Review, 2019’ provides a comprehensive overview of the drugs that are in the R&D pipeline by indication or molecule for Candidiasis. The report provides a thorough analysis of the distribution of the pipeline products by clinical trial stage, indication, company, therapy area and details such as clinical trial stage, sponsor, description on every product in the pipeline. Products in the preclinical and clinical stage along with dormant & discontinued pipeline candidates are included in the report. The report also covers additional insights such as epidemiology overview and current market scenario for Candidiasis.
The report on ‘Candidiasis – Pipeline Review, 2019’, which is built by following a robust research methodology involving primary interviews and desk research, provides a complete overview of the R&D activity and pipeline products to assist companies in developing growth strategies and identifying emerging players.